Predict your next investment

Essenlix company logo
HEALTHCARE | Biotechnology
essenlix.com

See what CB Insights has to offer

Founded Year

2013

Stage

Loan | Alive

Total Raised

$20.68M

Last Raised

$680K | 1 yr ago

About Essenlix

Essenlix develops an easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

Essenlix Headquarter Location

1 Deerpark Drive Suite R

Monmouth Junction, New Jersey, 08852,

United States

732-274-1020

Latest Essenlix News

Essenlix partners with Roche Diagnostics Norway to employ Essenlix’s iMOST platform for patient at-home test market

May 21, 2021

After an extended period of evaluation and collaboration, Roche Diagnostics Norway has selected Essenlix as its partner for the initiative and will employ Essenlix's iMOST – a breakthrough technology in at-home diagnostic testing – as the platform for its patient-at-home-test solution in Norway Essenlix's iMOST X-1. (Credit: PRNewswire / Essenlix Corporation) Essenlix Corporation, a premier developer, manufacturer, and provider of mobile instant health test solutions for personal, point-of-care, and clinical use using disruptive and proprietary advanced technology, today announced that it is partnering with Roche Diagnostics Norway to implement Essenlix’s iMOSTTM platform for the Patient At-Home Test market. The Norwegian healthcare service is facing significant capacity challenges, with an increasing number of patients and elderly in need of health services, as well as a reduced supply of health personnel. To address these challenges and provide better healthcare, the Norwegian healthcare system is advancing into a new era of medical distance follow-up and treatment, which requires innovative technologies that allow patients to perform safe, accurate, reliable, and easy-to-use healthcare tests at home. After an extended period of evaluation and collaboration, Roche Diagnostics Norway has selected Essenlix as its partner for the initiative and will employ Essenlix’s iMOST – a breakthrough technology in at-home diagnostic testing – as the platform for its patient-at-home-test solution in Norway. Essenlix iMOSTTM (instant Mobile Self Test) is an instant, mobile phone-based health test platform for personal, point-of-care, and clinical use. It is designed to allow any person to perform a diagnostic health test him/herself, accurately, anywhere, anytime, using a single drop of body fluid and a smartphone, within about 60 seconds, at a low cost, with the result sent immediately to medical professionals. iMOST, first of the type, fundamentally differs from traditional instruments and devices in several respects. First, it is “Intelligent Fault Tolerant,” delivering clinical lab-quality test results with good reliability, using a simple device and even under imperfect conditions in sample, device, process, and operation. Second, it is “All-in-One,” using one unique instrument/device to perform health test for nearly all sample types (blood, saliva, urine, swaps, sputum, breath, mucus, tissues, etc.) and for most major assay types (immunoassay, colorimetric assay, cytology and pathology, nucleic acid assay, etc. ), rather than using different sample holders and instruments. Third, it is instant (~60 secs) in test time, handheld, portable, easy-to-to-use, low-cost, and mobile-connected. As an example, iMOST Model X-1 uses only three pieces of hardware: a mobile phone, a match box sized adaptor, and a mail stamp-sized sample holder. It is the world’s smallest, simplest, and lowest-cost device for blood cell counting, as well as the device for performing immunoassay, colorimetric assay, cytology and pathology. iMOST’s uniqueness derives from new working principles developed at Essenlix in sample and bio-chemistry preparation, measurement methodology, and instrumentation, which are fundamentally different from conventional ones. These inventions are realized by outside-of-the-box thinking and uniquely implementing nanotechnology, advance imaging, nano-abled artificial intelligence/machine learning, and new bio/chemical processes into diagnostic testing. Essenlix is an integrated company that has a full range of capabilities in house, from biotechnology, hardware and software engineering, machine learning, to diagnostics instrumentation, as well as design, development, prototyping, and manufacturing. Essenlix has developed and built unique manufacturing lines with a capacity of over 10 million iMOST test cards per year. “For us at Roche Diagnostics Norway the partnership with Essenlix is important and exciting. Together we can make everyday life easier and more predictable for both patients and the healthcare system,” said Thorbjørn Halvorsen, Head of Medical Affairs, Roche Diagnostics Norway. “We are very proud that Roche Diagnostics Norway has selected Essenlix, through a rigorous process, as a partner to employ iMOST as test platform for Patient-at-Home testing in Norway. This is a further validation of the innovation and uniqueness of our platform,” said Dr. Stephen Y. Chou Co-Founder and Chairman of Essenlix. “This partnership is an excellent vehicle to further demonstrate and test the capabilities of Essenlix iMOST platform for personal, point-of-care, and clinical use in Norway. It is also an important step forward to make the iMOST platform a solution to the unmet need of instant personal health testing, providing a key missing link between personal health, remote monitoring and treatment, and e-health services in Norway,” added Dr. Chou. Source: Company Press Release

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Essenlix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Essenlix is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Essenlix Patents

Essenlix has filed 65 patents.

The 3 most popular patent topics include:

  • Analytical chemistry
  • Spectroscopy
  • Blood tests
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/16/2018

4/6/2021

Spectroscopy, Molecular biology, Optical devices, Laboratory equipment, Analytical chemistry

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/16/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/6/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Spectroscopy, Molecular biology, Optical devices, Laboratory equipment, Analytical chemistry

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Essenlix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Essenlix Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.